Earningsreport

Q1/2023 3/31/2023 EPS -0.870 ZacksConsensus -0.880 ActVsEst 0.010 - Beat

Relmada Therapeutics, Inc.  (RLMD) 
NASDAQ:AMEX Investor Relations: ir.relmada.com